Search Results - "Musliner, Thomas"

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population by Blazing, Michael A., MD, Giugliano, Robert P., MD, SM, Cannon, Christopher P., MD, Musliner, Thomas A., MD, Tershakovec, Andrew M., MD, MPH, White, Jennifer A., MS, Reist, Craig, PhD, McCagg, Amy, BS, Braunwald, Eugene, MD, Califf, Robert M., MD

“…Background The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) is evaluating the potential benefit for reduction in major…”
Get full text

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes by Cannon, Christopher P., MD, Giugliano, Robert P., MD, SM, Blazing, Michael A., MD, Harrington, Robert A., MD, Peterson, John L., MD, Sisk, Christine McCrary, BS, Strony, John, MD, Musliner, Thomas A., MD, McCabe, Carolyn H., BS, Veltri, Enrico, MD, Braunwald, Eugene, MD, Califf, Robert M., MD

“…Background Reduction in low-density lipoprotein cholesterol (LDL-C) improves clinical outcomes in patients with chronic coronary artery disease and acute…”
Get full text

Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia by Kusters, D. Meeike, MD, Caceres, Maria, MS, Coll, Mauricio, MD, Cuffie, Cynthia, MD, Gagné, Claude, MD, Jacobson, Marc S., MD, FAHA, Kwiterovich, Peter O., MD, Lee, Raymond, BS, Lowe, Robert S., PhD, Massaad, Rachid, MS, McCrindle, Brian W., MD, MPH, Musliner, Thomas A., MD, Triscari, Joseph, PhD, Kastelein, John J.P., MD, PhD

“…Objectives To evaluate the lipid-altering efficacy and safety of ezetimibe monotherapy in young children with heterozygous familial hypercholesterolemia (HeFH)…”
Get full text

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes by Cannon, Christopher P, Blazing, Michael A, Giugliano, Robert P, McCagg, Amy, White, Jennifer A, Theroux, Pierre, Darius, Harald, Lewis, Basil S, Ophuis, Ton Oude, Jukema, J. Wouter, De Ferrari, Gaetano M, Ruzyllo, Witold, De Lucca, Paul, Im, KyungAh, Bohula, Erin A, Reist, Craig, Wiviott, Stephen D, Tershakovec, Andrew M, Musliner, Thomas A, Braunwald, Eugene, Califf, Robert M

“…In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At…”
Get full text

Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin by Nanna, Michael G., Navar, Ann Marie, Giugliano, Robert P., White, Jennifer A., Lokhnygina, Yuliya, Mitchel, Yale B., Musliner, Thomas A., Cannon, Christopher P., Blazing, Michael A.

Get full text

An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design by Califf, Robert M., MD, Lokhnygina, Yuliya, PhD, Cannon, Christopher P., MD, Stepanavage, Michael E., MS, McCabe, Carolyn H., BS, Musliner, Thomas A., MD, Pasternak, Richard C., MD, Blazing, Michael A., MD, Giugliano, Robert P., MD, SM, Harrington, Robert A., MD, Braunwald, Eugene, MD

“…Since the original publication of the IMPROVE-IT Trial design,1 controversy over the impact of ezetimibe on the risk of cardiovascular events, as well as the…”
Get full text

On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) by Blazing, Michael A., MD, Giugliano, Robert P., MD, SM, de Lemos, James A., MD, Cannon, Christopher P., MD, Tonkin, Andrew, MBBS, MD, Ballantyne, Christie M., MD, Lewis, Basil S., MD, Musliner, Thomas A., MD, Tershakovec, Andrew M., MD, MPH, Lokhnygina, Yuliya, PhD, White, Jennifer A., MS, Reist, Craig, PhD, McCagg, Amy, BS, Braunwald, Eugene, MD

“…Abstract Background We aimed to determine the efficacy and safety of adding ezetimibe (Ez) to simvastatin (S) in a post-acute coronary syndrome (ACS)…”
Get full text

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia by Gagné, Claude, Bays, Harold E, Weiss, Stuart R, Mata, Pedro, Quinto, Katherine, Melino, Michael, Cho, Meehyung, Musliner, Thomas A, Gumbiner, Barry

“…Ezetimibe is a lipid-lowering drug that inhibits the intestinal absorption of dietary and biliary cholesterol by blocking passage across the intestinal wall…”
Get full text

Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin by Lakoski, Susan G, Xu, Fang, Vega, Gloria L, Grundy, Scott M, Chandalia, Manisha, Lam, Chun, Lowe, Robert S, Stepanavage, Michael E, Musliner, Thomas A, Cohen, Jonathan C, Hobbs, Helen H

“…Context: The level and duration of exposure to circulating low-density lipoprotein-cholesterol (LDL-C) are major contributors to coronary atherosclerosis…”
Get full text

Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia by Toth, Peter P., Catapano, Alberico L., Farnier, Michel, Foody, Joanne, Tomassini, Joanne E., Jensen, Erin, Polis, Adam B., Hanson, Mary E., Musliner, Thomas A., Tershakovec, Andrew M.

“…Statin therapy is associated with a slightly increased risk of developing diabetes mellitus and insulin resistance in patients without diabetes. Ezetimibe…”
Get full text

Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT by Giugliano, Robert P, Gencer, Baris, Wiviott, Stephen D, Park, Jeong-Gun, Fuchs, Charles S, Goessling, Wolfram, Musliner, Thomas A, Tershakovec, Andrew M, Blazing, Michael A, Califf, Robert, Cannon, Christopher P, Braunwald, Eugene

“…BACKGROUNDAn increased risk of malignancy was reported with simvastatin/ezetimibe in 1,873 patients in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis)…”
Get full text

Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men by Sudhop, Thomas, Reber, Michael, Tribble, Diane, Sapre, Aditi, Taggart, William, Gibbons, Patrice, Musliner, Thomas, von Bergmann, Klaus, Lütjohann, Dieter

“…This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or…”
Get full text

Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures: Results From the Fracture Intervention Trial by Cummings, Steven R, Black, Dennis M, Thompson, Desmond E, Applegate, William B, Barrett-Connor, Elizabeth, Musliner, Thomas A, Palermo, Lisa, Prineas, Ronald, Rubin, Susan M, Scott, Jean C, Vogt, Thomas, Wallace, Robert, Yates, A. John, LaCroix, Andrea Z, for the Fracture Intervention Trial Research Group

“…CONTEXT.— Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk have not been studied…”
Get full text

Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia by Assmann, Gerd, Kannenberg, Frank, Ramey, Dena R., Musliner, Thomas A., Gutkin, Stephen W., Veltri, Enrico P.

“…ABSTRACT Background: Levels of cholesterol are regulated by its synthesis, absorption, and elimination. Plasma levels of phytosterols (e.g., sitosterol,…”
Get full text

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) by PEDERSEN, T. R, OLSSON, A. G, MIETTINEN, T, CHRISTOPHERSEN, B, TOBERT, J. A, MUSLINER, T. A, COOK, T. J, FAERGEMAN, O, KJEKSHUS, J, WEDEL, H, BERG, K, WILHELMSEN, L, HAGHFELT, T, THORGEIRSSON, G, PYÖRÄLÄ, K

“…The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with coronary heart disease (CHD) and serum cholesterol 5.5 to 8.0 mmol/L (213 to 310…”
Get full text

Intestinal sterol transporters and cholesterol absorption inhibition by Davis, Jr, Harry R, Tershakovec, Andrew M, Tomassini, Joanne E, Musliner, Thomas

“…Statin therapy is the mainstay of lipid-lowering therapy; however, many patients, particularly those at high risk, do not achieve sufficient LDL-cholesterol…”
Get full text

Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S) by Pedersen, Terje R, Kjekshus, John, Pyörälä, Kalevi, Olsson, Anders G, Cook, Thomas J, Musliner, Thomas A, Tobert, Jonathan A, Haghfelt, Torben

“…In patients participating in the Scandinavian Simvastatin Survival Study, cholesterol lowering with simvastatin reduced the incidence of carotid bruits and…”
Get full text

Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia by Tribble, Diane L, Farnier, Michel, Macdonell, Geraldine, Perevozskaya, Inna, Davies, Michael J, Gumbiner, Barry, Musliner, Thomas A

“…Abstract Coadministration of fenofibrate and ezetimibe (FENO + EZE) produced complementary and favorable effects on the major lipids and lipoproteins,…”
Get full text

Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo by Giugliano, Robert P., Gencer, Baris, Wiviott, Stephen D., Park, Jeong-Gun, Fuchs, Charles S., Goessling, Wolfram, Musliner, Thomas A., Tershakovec, Andrew M., Blazing, Michael A., Califf, Robert, Cannon, Christopher P., Braunwald, Eugene

“…An increased risk of malignancy was reported with simvastatin/ezetimibe in 1,873 patients in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial. The…”
Get full text

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris : Findings from the Scandinavian Simvastatin Survival Study (4S) by MIETTINEN, T. A, PYÖRÄLÄ, K, OLSSON, A. G, MUSLINER, T. A, COOK, T. J, FAERGEMAN, O, BERG, K, PEDERSEN, T, KJEKSHUS, J

“…The Scandinavian Simvastatin Survival Study (4S) demonstrated pronounced reductions in mortality and major coronary events in a cohort of patients with…”
Get full text